Uncommon efforts for an uncommon tumor: the case for development of newer systemic therapies for advanced thymic epithelial tumors

Mohammed Amine Achhal El Kadmiri, Arun Rajan


Thymic epithelial tumors (TETs) are a family of rare cancers that exhibit diverse histology and variable clinical behavior. The prognosis associated with TETs, especially thymomas, is generally good relative to other solid tumors with 5-year survival rates of 67% to 93% in patients with locally advanced disease that can be completely resected (1).